Journey Medical Corporation (DERM) Covered Calls
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on the development and commercialization of prescription products for dermatological conditions. The firm utilizes an efficient sales and marketing model to promote a portfolio of branded and generic therapies, including treatments for rosacea, acne, and excessive sweating. By identifying and acquiring underutilized assets, the company aims to improve patient outcomes and brand value.
You can sell covered calls on Journey Medical Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DERM (prices last updated Tue 4:16 PM ET):
| Journey Medical Corporation (DERM) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 4.92 | -0.27 | 4.80 | 4.92 | 217K | - | 0.1 |
| Covered Calls For Journey Medical Corporation (DERM) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 5 | 0.00 | 4.92 | 0.0% | 0.0% | |
| Jun 18 | 5 | 0.00 | 4.92 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Journey Medical Corporation (DERM) is a specialized pharmaceutical firm that operates a high-efficiency commercial platform dedicated to the dermatology market. The company, a subsidiary of Fortress Biotech, leverages a lean sales infrastructure to market a diverse portfolio of FDA-approved products. Its primary mission is to acquire, develop, and commercialize differentiated therapies that address high-volume dermatological needs such as inflammatory rosacea and acne.
The Emrosi Launch and 2026 Strategic Pivot
2025 served as a pivotal year for the firm with the commercial launch of Emrosi™ (minocycline hydrochloride extended-release capsules) for the treatment of papulopustular rosacea. After receiving FDA approval in late 2024, Emrosi generated $14.7 million in net revenue during its first three quarters on the market.
By early 2026, the company successfully expanded payer access for Emrosi to over 100 million commercial lives in the United States. This rapid market penetration has helped offset the $6.5 million year-over-year revenue decline in its legacy Accutane® business, which continues to face intense competitive pressure. In March 2026, management reported that Adjusted EBITDA reached $2.9 million for the 2025 fiscal year, signaling a significant shift toward operational profitability as the product mix favors higher-margin, internally developed assets.
Competitive Landscape
The dermatology pharmaceutical sector is highly competitive, with the company vying for physician mindshare against established specialty pharma players and emerging biotech firms. Key competitors include:
- Assertio Holdings, Inc.: A specialty pharmaceutical company that manages a portfolio of branded products in the pain and dermatology space. They compete through a similar acquisition-focused business model and localized sales force execution.
- MediWound Ltd.: A biopharmaceutical company focused on enzymatic therapeutics for tissue repair and regeneration. They compete in the specialty dermatology and wound care markets, often targeting overlapping clinical specialists and procurement budgets.
- Fortress Biotech, Inc.: The company’s founding parent and a major player in the biotechnology sector. While they act as a strategic partner, they also compete for institutional investment and research talent within the broader pharmaceutical development ecosystem.
- Ironwood Pharmaceuticals, Inc.: A leading healthcare company that develops and commercializes gastrointestinal and specialty therapies. They compete for market access and commercial resources within the highly regulated specialty pharmacy landscape.
Strategic Outlook and Capital Allocation
The firm is currently prioritizing "Operating Margin Expansion" by transitioning Emrosi from a launch phase to a mature commercial asset, which involves reducing reliance on co-pay bridging programs. Strategic efforts in 2026 are also focused on launching one or two incremental dermatology products to further leverage the existing sales organization.
Financially, the company is maintaining a disciplined approach to its balance sheet, ending 2025 with $24.1 million in cash. In January 2026, the firm filed a $150 million S-3 shelf registration to provide flexible financing for future growth initiatives. Management remains focused on securing "consensus treatment guidelines" inclusion for Emrosi, which they believe will be a primary driver of long-term prescription growth and shareholder value through 2027.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | CAR covered calls | |
| 2. | NVDA covered calls | 7. | HYG covered calls | 2. | USO covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | CMPX covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | QS covered calls | |
| 5. | TLT covered calls | 10. | EEM covered calls | 5. | NOW covered calls | |
Want more examples? DEO Covered Calls | DES Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
